Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACGNNASDAQ:ATHANASDAQ:BCDANYSE:CLDI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACGNAceragen$0.38$0.46$0.36▼$16.00$3.20MN/AN/AN/AATHAAthira Pharma$0.34+1.8%$0.27$0.22▼$3.67$13.12M3.03417,518 shs525,623 shsBCDABioCardia$2.16-0.7%$2.23$1.63▼$5.04$11.16M0.82289,275 shs9,269 shsCLDICalidi Biotherapeutics$0.35-3.2%$0.45$0.34▼$3.89$11.22M1.21896,128 shs350,890 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACGNAceragen0.00%0.00%0.00%0.00%0.00%ATHAAthira Pharma+9.16%+14.62%+18.28%-5.77%-86.48%BCDABioCardia-0.46%+2.84%-13.20%-15.89%-50.90%CLDICalidi Biotherapeutics+2.19%-8.37%-24.02%-57.07%+36,469,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACGNAceragenN/AN/AN/AN/AN/AN/AN/AN/AATHAAthira Pharma3.3794 of 5 stars3.05.00.00.02.82.51.3BCDABioCardia3.4908 of 5 stars3.85.00.00.02.22.50.6CLDICalidi Biotherapeutics1.8828 of 5 stars3.53.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACGNAceragen 0.00N/AN/AN/AATHAAthira Pharma 2.00Hold$13.834,017.06% UpsideBCDABioCardia 3.50Strong Buy$25.001,060.09% UpsideCLDICalidi Biotherapeutics 3.00Buy$10.002,732.86% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACGNAceragen$4.86M0.66N/AN/AN/A∞ATHAAthira PharmaN/AN/AN/AN/A$3.42 per shareN/ABCDABioCardia$3K3,719.53N/AN/A($1.11) per share-1.94CLDICalidi Biotherapeutics$50K224.46N/AN/A($2.32) per share-0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACGNAceragen-$23.36MN/A0.00∞N/AN/AN/AN/AN/AATHAAthira Pharma-$117.67M-$2.07N/AN/AN/AN/A-115.62%-88.94%7/30/2025 (Estimated)BCDABioCardia-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)CLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/ALatest ACGN, CLDI, BCDA, and ATHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACGNAceragenN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACGNAceragenN/AN/AN/AATHAAthira PharmaN/A2.952.95BCDABioCardiaN/A1.781.78CLDICalidi BiotherapeuticsN/A0.190.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACGNAceragen0.05%ATHAAthira Pharma57.12%BCDABioCardia20.57%CLDICalidi Biotherapeutics12.53%Insider OwnershipCompanyInsider OwnershipACGNAceragen26.45%ATHAAthira Pharma22.10%BCDABioCardia20.00%CLDICalidi Biotherapeutics24.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACGNAceragen268.42 million6.20 millionNot OptionableATHAAthira Pharma4039.04 million31.01 millionOptionableBCDABioCardia405.18 million3.67 millionOptionableCLDICalidi Biotherapeutics3831.79 million20.04 millionN/AACGN, CLDI, BCDA, and ATHA HeadlinesRecent News About These CompaniesCalidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual MeetingJune 3 at 7:52 AM | pipelinereview.comCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 16, 2025 | finanznachrichten.deCalidi Biotherapeutics Strengthens Leadership Team and Advances Antitumor Virotherapy Platform with New CEO and Chief Medical Officer AppointmentsMay 16, 2025 | nasdaq.comCalidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?May 16, 2025 | zacks.comCalidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 15, 2025 | tmcnet.comCalidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual MeetingApril 28, 2025 | finance.yahoo.comCalidi reports inducement grant unders NYSE American guideApril 26, 2025 | markets.businessinsider.comCalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711April 25, 2025 | globenewswire.comCalidi appoints Eric Poma as CEO, directorApril 24, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and DirectorApril 23, 2025 | manilatimes.netCalidi announces FDA clearance of IND application for CLD-201April 18, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid TumorsApril 17, 2025 | markets.businessinsider.comCalidi appoints Guy Travis Clifton as CMO, Consultant, AdvisorApril 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and AdvisorApril 10, 2025 | finance.yahoo.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational HighlightsMarch 31, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 31, 2025 | globenewswire.comCalidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent GliomaMarch 29, 2025 | nasdaq.comCalidi prices 3.33M shares at 65c in registered direct offeringMarch 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 28, 2025 | globenewswire.comCalidi, City of Hope provide update on Phase 1 trial with CLD-101March 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACGN, CLDI, BCDA, and ATHA Company DescriptionsAceragen NASDAQ:ACGNAceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.Athira Pharma NASDAQ:ATHA$0.34 +0.01 (+1.82%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.BioCardia NASDAQ:BCDA$2.15 -0.02 (-0.92%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Calidi Biotherapeutics NYSE:CLDI$0.35 -0.01 (-3.48%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
